IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 1, 2012, Pages

  Krueger, James G ^a   Fretzin, Scott ^b   Suárez Fariñas, Mayte ^a   Haslett, Patrick A ^c   Phipps, Krista M ^c   Cameron, Gregory S ^c   McColm, Juliet ^c   Katcherian, Artemis ^a   Cueto, Inna ^a   White, Traci ^a   Banerjee, Subhashis ^c   Hoffman, Robert W ^c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Dawes/Fretzin Dermatology Group   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

IL 17; Psoriasis; TNF

Indexed keywords

CELL PROTEIN; ETANERCEPT; INNATE DEFENSE PEPTIDE; INTERLEUKIN 17; IXEKIZUMAB; MESSENGER RNA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENDRITIC CELL; DERMIS; EPIDERMIS; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; INFLAMMATORY GENE; KERATINOCYTE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN DEFECT; SKIN INFILTRATE; SKINFOLD; T LYMPHOCYTE;

EID: 84862860846     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.04.024     Document Type: Article

References (56)

1. M.W. Greaves, and G.D. Weinstein Treatment of psoriasis N Engl J Med 332 1995 581 588
2. M.A. Lowes, A.M. Bowcock, and J.G. Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
3. S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt Circulating Th17, Th22, and Th1 cells are increased in psoriasis J Invest Dermatol 130 2010 1373 1383
4. I. Kryczek, A.T. Bruce, J.E. Gudjonsson, A. Johnston, A. Aphale, and L. Vatan Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis J Immunol 181 2008 4733 4741
5. M.A. Lowes, T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L.C. Zaba, and A.S. Haider Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells J Invest Dermatol 128 2008 1207 1211 (Pubitemid 351543220)
6. K.E. Nograles, L.C. Zaba, A. Shemer, J. Fuentes-Duculan, I. Cardinale, and T. Kikuchi IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells J Allergy Clin Immunol 123 2009 1244 1252
7. L.C. Zaba, J. Fuentes-Duculan, N.J. Eungdamrong, M.V. Abello, I. Novitskaya, and K.C. Pierson Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells J Invest Dermatol 129 2009 79 88
8. C.Y. Kao, Y. Chen, P. Thai, S. Wachi, F. Huang, and C. Kim IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways J Immunol 173 2004 3482 3491 (Pubitemid 39142059)
9. S.C. Liang, X.Y. Tan, D.P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, and M. Collins Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides J Exp Med 203 2006 2271 2279 (Pubitemid 44498362)
10. E. Guttman-Yassky, M.A. Lowes, J. Fuentes-Duculan, L.C. Zaba, I. Cardinale, and K.E. Nograles Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis J Immunol 181 2008 7420 7427
11. M.A. Stark, Y. Huo, T.L. Burcin, M.A. Morris, T.S. Olson, and K. Ley Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17 Immunity 22 2005 285 294 (Pubitemid 40387471)
12. H. Blumberg, D. Conklin, W.F. Xu, A. Grossmann, T. Brender, and S. Carollo Interleukin 20: discovery, receptor identification, and role in epidermal function Cell 104 2001 9 19 (Pubitemid 32144968)
13. K. Boniface, F.X. Bernard, M. Garcia, A.L. Gurney, J.C. Lecron, and F. Morel IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes J Immunol 174 2005 3695 3702 (Pubitemid 40354080)
14. K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat IL-22 increases the innate immunity of tissues Immunity 21 2004 241 254 (Pubitemid 39094053)
15. K. Wolk, E. Witte, E. Wallace, W.D. Docke, S. Kunz, and K. Asadullah IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis Eur J Immunol 36 2006 1309 1323
16. A. Di Cesare, P. Di Meglio, and F.O. Nestle The IL-23/Th17 axis in the immunopathogenesis of psoriasis J Invest Dermatol 129 2009 1339 1350
17. E. Lee, W.L. Trepicchio, J.L. Oestreicher, D. Pittman, F. Wang, and F. Chamian Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125 130 (Pubitemid 38076484)
18. G. Piskin, R.M. Sylva-Steenland, J.D. Bos, and M.B. Teunissen In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin J Immunol 176 2006 1908 1915 (Pubitemid 43134336)
19. F. Capon, M.P. Di, J. Szaub, N.J. Prescott, C. Dunster, and L. Baumber Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis Hum Genet 122 2007 201 206 (Pubitemid 47241785)
20. M. Cargill, S.J. Schrodi, M. Chang, V.E. Garcia, R. Brandon, and K.P. Callis A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Am J Hum Genet 80 2007 273 290 (Pubitemid 46175676)
21. P. Di Meglio, A. Di Cesare, U. Laggner, C.C. Chu, L. Napolitano, and F. Villanova The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans PLoS One 6 2011 e17160
22. H.L. Ma, S. Liang, J. Li, L. Napierata, T. Brown, and S. Benoit IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation J Clin Invest 118 2008 597 607 (Pubitemid 351206549)
23. Y. Zheng, D.M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, and J. Wu Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Nature 445 2007 648 651 (Pubitemid 46232884)
24. S.M. Sa, P.A. Valdez, J. Wu, K. Jung, F. Zhong, and L. Hall The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis J Immunol 178 2007 2229 2240 (Pubitemid 46233421)
25. K.E. Nograles, L.C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suarez-Farinas, and I. Cardinale Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways Br J Dermatol 159 2008 1092 1102
26. W. Hueber, D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, and G. Bruin Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci Transl Med 2 2010 52ra72
27. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, and E. Edson-Heredia Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2012 1190 1199
28. L.C. Zaba, M. Suarez-Farinas, J. Fuentes-Duculan, K.E. Nograles, E. Guttman-Yassky, and I. Cardinale Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes J Allergy Clin Immunol 124 2009 1022-10
29. F. Chamian, M.A. Lowes, S.L. Lin, E. Lee, T. Kikuchi, and P. Gilleaudeau Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris Proc Natl Acad Sci U S A 102 2005 2075 2080 (Pubitemid 40262014)
30. M. Suarez-Farinas, A. Haider, and K.M. Wittkowski " Harshlighting" small blemishes on microarrays BMC Bioinformatics 6 2005 65
31. J.E. Gudjonsson, J. Ding, A. Johnston, T. Tejasvi, A.M. Guzman, and R.P. Nair Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models J Invest Dermatol 130 2010 1829 1840
32. M. Suarez-Farinas, M.A. Lowes, L.C. Zaba, and J.G. Krueger Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA) PLoS One 5 2010 e10247
33. Y. Yao, L. Richman, C. Morehouse, R.M. de los, B.W. Higgs, and A. Boutrin Type I interferon: potential therapeutic target for psoriasis? PLoS One 3 2008 e2737
34. X. Zhou, J.G. Krueger, M.C. Kao, E. Lee, F. Du, and A. Menter Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array Physiol Genomics 13 2003 69 78 (Pubitemid 37129170)
35. W.E. Johnson, C. Li, and A. Rabinovic Adjusting batch effects in microarray expression data using empirical Bayes methods Biostatistics 8 2007 118 127 (Pubitemid 44906106)
36. A. Chiricozzi, E. Guttman-Yassky, M. Suarez-Farinas, K.E. Nograles, S. Tian, and I. Cardinale Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis J Invest Dermatol 131 2011 677 687
37. A.S. Haider, M.A. Lowes, M. Suarez-Farinas, L.C. Zaba, I. Cardinale, and A. Khatcherian Identification of cellular pathways of "type 1, " Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis J Immunol 180 2008 1913 1920
38. L.M. Johnson-Huang, M. Suarez-Farinas, M. Sullivan-Whalen, P. Gilleaudeau, J.G. Krueger, and M.A. Lowes Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques J Invest Dermatol 130 2010 2654 2663
39. K.M. Wittkowski, E. Lee, R. Nussbaum, F.N. Chamian, and J.G. Krueger Combining several ordinal measures in clinical studies Stat Med 23 2004 1579 1592 (Pubitemid 38660410)
40. G.G. Krueger, R.G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, and Y. Wang A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis N Engl J Med 356 2007 580 592 (Pubitemid 46220818)
41. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
42. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312 (Pubitemid 40933433)
43. D. Ganguly, G. Chamilos, R. Lande, J. Gregorio, S. Meller, and V. Facchinetti Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 J Exp Med 206 2009 1983 1994
44. T. Aranami, and T. Yamamura Th17 Cells and autoimmune encephalomyelitis (EAE/MS) Allergol Int 57 2008 115 120 (Pubitemid 351897665)
45. C. Diveu, M.J. McGeachy, and D.J. Cua Cytokines that regulate autoimmunity Curr Opin Immunol 20 2008 663 668
46. M.J. McGeachy, and D.J. Cua The link between IL-23 and Th17 cell-mediated immune pathologies Semin Immunol 19 2007 372 376 (Pubitemid 351274049)
47. M. Gandhi, E. Alwawi, and K.B. Gordon Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis Semin Cutan Med Surg 29 2010 48 52
48. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
49. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
50. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis N Engl J Med 361 2009 496 509
51. H. Sofen, S. Smith, R. Matheson, C. Leonardi, C. Calderon, and E. Bouman-Thio Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis Br J Dermatol 2012 165 e10
52. B.E. Strober, J.J. Crowley, P.S. Yamauchi, M. Olds, and D.A. Williams Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br J Dermatol 165 2011 661 668
53. A. Puel, S. Cypowyj, J. Bustamante, J.F. Wright, L. Liu, and H.K. Lim Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity Science 332 2011 65 68
54. L.C. Zaba, I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suarez-Farinas, and J. Fuentes-Duculan Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses J Exp Med 204 2007 3183 3194
55. E. Guttman-Yassky, K.E. Nograles, and J.G. Krueger Contrasting pathogenesis of atopic dermatitis and psoriasis - part II: immune cell subsets and therapeutic concepts J Allergy Clin Immunol 127 2011 1420 1432
56. E. Guttman-Yassky, K.E. Nograles, and J.G. Krueger Contrasting pathogenesis of atopic dermatitis and psoriasis - part I: clinical and pathologic concepts J Allergy Clin Immunol 127 2011 1110 1118